S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:ABMD

Abiomed Earnings Date, Estimates, & History

$300.63
-11.81 (-3.78%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$295.71
$316.62
50-Day Range
$300.63
$371.35
52-Week Range
$254.41
$387.40
Volume
275,988 shs
Average Volume
238,406 shs
Market Capitalization
$13.68 billion
P/E Ratio
92.79
Dividend Yield
N/A
Beta
1.27

Earnings Summary

Upcoming
Earnings Date
Jan. 27
Estimated

Actual EPS
(Oct. 27)
$1.03
Beat By $0.05

Consensus EPS
(Oct. 27)
$0.98

Last Year's Q4 EPS
(11/3/2020)
$1.36

Skip Charts & View Estimated and Actual Earnings Data

Abiomed Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Abiomed Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Abiomed (NASDAQ:ABMD) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20214$0.68$1.17$1.00 
Q2 20214$0.83$1.17$1.05 
Q3 20215$0.97$1.29$1.16 
Q4 20215$1.00$1.39$1.15 
FY 202118$3.48$5.02$4.35
Q1 20225$0.98$1.39$1.16 
Q2 20225$0.92$1.39$1.13 
Q3 20224$1.00$1.35$1.14 
Q4 20224$1.09$1.25$1.15 
FY 202218$3.99$5.38$4.57
Q1 20233$0.98$1.22$1.07 
Q2 20233$1.07$1.24$1.17 
Q3 20233$1.28$1.42$1.33 
Q4 20233$1.28$1.44$1.34 
FY 202312$4.61$5.32$4.92

ABMD Earnings Information

Abiomed last posted its quarterly earnings data on October 27th, 2021. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.05. The firm had revenue of $248.10 million for the quarter, compared to analyst estimates of $248.06 million. Its quarterly revenue was up 18.3% compared to the same quarter last year. Abiomed has generated $3.24 earnings per share over the last year ($3.24 diluted earnings per share) and currently has a price-to-earnings ratio of 92.8. Earnings for Abiomed are expected to grow by 18.44% in the coming year, from $4.23 to $5.01 per share. Abiomed has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 27th, 2022 based off prior year's report dates.

Abiomed (NASDAQ:ABMD) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
1/27/2022
(Estimated)
        
10/27/20219/30/2021$0.98$1.03+$0.05$0.82$248.06 million$248.10 million    
8/3/20216/30/2021$1.06$1.41+$0.35$2.79$243.81 million$252.59 million    
4/28/20213/31/2021$1.10$1.24+$0.14$1.24$231.13 million$241.30 million  
1/27/202112/31/2020$1.15$1.35+$0.20$0.99$226.31 million$231.66 million  
11/3/20209/30/2020$0.87$1.36+$0.49$0.66$202.89 million$209.80 million  
8/6/20206/30/2020$0.20$0.58+$0.38$0.18$144.12 million$164.90 million  
4/30/20203/31/2020$0.96$0.70($0.26)$1.30$209.58 million$206.66 million  
2/6/2020Q4 19$1.09$1.51+$0.42$0.71$226.92 million$221.60 million  
10/31/2019Q2 2020$0.93$1.03+$0.10$1.78$206.45 million$204.97 million  
8/1/2019Q1 2020$0.99$1.00+$0.01$0.07$210.96 million$207.70 million
5/2/20193/31/2019$1.07$1.60+$0.53$0.54$218.88 million$207.08 million  
1/31/201912/31/2018$0.94$0.97+$0.03$0.97$200.60 million$200.56 million
11/1/20189/30/2018$0.73$1.09+$0.36$0.53$175.41 million$181.78 million
7/26/2018Q1 2019$0.80$1.95+$1.15($0.39)$173.87 million$180.01 million
5/3/2018Q4 2018$0.64$0.80+$0.16$0.80$164.30 million$174.44 million
2/1/2018Q3 2018$0.50$0.70+$0.20$1.11$154.00 million$154.00 million
10/26/2017Q2 2018$0.38$0.54+$0.16$0.34$131.18 million$132.80 million
7/27/2017Q1 2018$0.42$0.45+$0.03$0.08$130.83 million$132.47 million
5/4/2017Q4 2017$0.33$0.33$0.33$122.82 million$124.68 million  
1/26/2017Q317$0.29$0.34+$0.05$0.34$112.71 million$114.70 million  
10/27/2016Q217$0.24$0.20($0.04)$0.20$103.16 million$103.00 million  
7/28/2016Q117$0.23$0.29+$0.06$0.29$97.23 million$103.00 million  
5/3/2016Q416$0.19$0.24+$0.05$0.24$90.52 million$94.00 million
2/4/2016Q316$0.15$0.23+$0.08$0.23$80.04 million$85.80 million  
10/29/2015Q2$0.13$0.17+$0.04$0.17$74.56 million$76.30 million  
8/4/2015Q116$0.08$0.20+$0.12$0.20$66.27 million$73.40 million
5/5/2015Q415$0.12$0.28+$0.16($1.68)$62.55 million$67.60 million
1/27/2015Q315$0.03$0.30+$0.27$0.30$53.20 million$62.00 million
10/30/2014Q215$0.02$0.09+$0.07$0.09$48.80 million$51.80 million
7/31/2014Q115$0.02($0.04)($0.06)($0.04)$297.10 million$48.80 million  
5/1/2014Q414$0.09$0.09$0.09$50.93 million$50.40 million  
1/30/2014Q3 2014$0.04$0.11+$0.07$0.11$46.00 million$46.20 million  
11/6/2013Q2 2014$0.03$0.03$0.03$43.75 million$44.30 million  
8/1/2013Q1 2014$0.06$0.07+$0.01$0.18$42.93 million$42.70 million  
5/2/2013Q4 2013$0.07$0.09+$0.02$0.09$41.87 million$43.70 million  
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 million  
11/1/2012Q213$0.05$0.20+$0.15$37.47 million$37.40 million
8/2/2012$0.10$0.16+$0.06
5/16/2012$0.07$0.07
2/3/2012($0.01)$0.07+$0.08
11/3/2011($0.09)$0.02+$0.11  
8/4/2011($0.06)($0.03)+$0.03  
5/18/2011($0.04)($0.05)($0.01)  
2/3/2011($0.09)($0.02)+$0.07
11/4/2010Q2 2011($0.14)($0.09)+$0.05($0.09)
8/4/2010Q1 2011($0.14)($0.14)($0.12)
5/19/2010Q4 2010($0.12)($0.11)+$0.01($0.23)
2/4/2010Q3 2010($0.18)($0.11)+$0.07($0.10)
11/5/2009Q2 2010($0.21)($0.21)($0.21)
8/6/2009Q1 2010($0.20)($0.20)($0.19)
5/12/2009Q4 2009($0.17)($0.22)($0.05)($0.21)
2/5/2009Q3 2009($0.17)($0.20)($0.03)($0.19)
11/10/2008Q2 2009($0.21)($0.18)+$0.03($0.18)
8/7/2008Q1 2009($0.21)($0.28)($0.07)($0.28)
5/21/2008Q4 2008($0.19)($0.25)($0.06)($0.04)
2/7/2008Q3 2008($0.20)($0.26)($0.06)($0.26)
(Earnings results data provided by Zacks Investment Research)












Abiomed (NASDAQ:ABMD) Earnings Frequently Asked Questions

When is Abiomed's earnings date?

Abiomed has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, January 27th, 2022 based off last year's report dates. Learn more on ABMD's earnings history

Did Abiomed beat their earnings estimates last quarter?

In the previous quarter, Abiomed (NASDAQ:ABMD) reported $1.03 earnings per share (EPS) to beat the analysts' consensus estimate of $0.98 by $0.05. Learn more on ABMD's earnings details

How can I listen to Abiomed's earnings conference call?

The conference call for Abiomed's latest earnings report can be listened to online. Listen to Conference Call

How can I read Abiomed's conference call transcript?

The conference call transcript for Abiomed's latest earnings report can be read online. Read Transcript

How much revenue does Abiomed generate each year?

Abiomed (NASDAQ:ABMD) has a recorded annual revenue of $847.52 million.

How much profit does Abiomed generate each year?

Abiomed (NASDAQ:ABMD) has a recorded net income of $225.52 million. ABMD has generated $3.24 earnings per share over the last four quarters.

What is Abiomed's price-to-earnings ratio?

Abiomed (NASDAQ:ABMD) has a trailing price-to-earnings ratio of 92.79 and a forward price-to-earnings ratio of 71.07. The price/earnings-to-growth ratio is 3.69.

What is Abiomed's EPS forecast for next year?

Abiomed's earnings are expected to grow from $4.23 per share to $5.01 per share in the next year, which is a 18.44% increase.

This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.